Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo, Lilly rivals explore booming weight-loss drug market entry
09:58am, Friday, 08'th Dec 2023
Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up thr
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
05:30am, Friday, 08'th Dec 2023
Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
10:32am, Thursday, 07'th Dec 2023
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Goldman Sachs money manager digs into three themes for long-term growth
11:27am, Tuesday, 05'th Dec 2023
Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, whi
AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why
11:14am, Tuesday, 05'th Dec 2023
JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top
Novo Nordisk: From diabetes to weight loss to obesity preventions
09:26am, Tuesday, 05'th Dec 2023
Having developed a blockbuster diabetes treatment that has gained huge traction in the weight loss market, Novo Nordisk (NYSE:NVO) is now expanding its focus to include the prevention of obesity, acc
No more exercising? President RFK Jr.?
05:45am, Tuesday, 05'th Dec 2023
Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels wil
Ozempic vs. Mounjaro:: Battle of the bulge
10:16am, Monday, 04'th Dec 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
07:43am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic
05:40am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No
3 No-Brainer Growth Stocks to Buy in December
06:54am, Sunday, 03'rd Dec 2023
Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
09:30am, Saturday, 02'nd Dec 2023
Novo Nordisk's weight-loss products soared in popularity this year. The company remains a leader in this area thanks to its innovations.
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
05:53am, Saturday, 02'nd Dec 2023
Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity ind
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
12:22pm, Friday, 01'st Dec 2023
Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
08:20am, Friday, 01'st Dec 2023
Novo Nordisk is a big name in diabetes and obesity care. Both Wegovy and Ozempic are fast-growing drugs with a ton of upside.
